Strongyloides stercoralis hyperinfection syndrome: a case series and a review of the literature

Infection

Volumn 43, Issue 6, 2015, Pages 691-698

  Geri, Guillaume ^a,b   Rabbat, Antoine ^a   Mayaux, Julien ^d   Zafrani, Lara ^b,e   Chalumeau Lemoine, Ludivine ^f   Guidet, Bertrand ^g,h   Azoulay, Elie ^b,e   Pène, Frédéric ^a,b,c  

^a Institut Cochin   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT COCHIN   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h SORBONNE UNIVERSITÉ   (France)

Author keywords

Eosinophilia; Hyperinfection; Strongyloides stercoralis

Indexed keywords

ALBENDAZOLE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; IVERMECTIN; TIABENDAZOLE;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; CASE STUDY; CLINICAL FEATURE; CORTICOSTEROID THERAPY; FEMALE; HUMAN; HYPEREOSINOPHILIA; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RETROSPECTIVE STUDY; SHOCK; STRONGYLOIDES STERCORALIS; STRONGYLOIDES STERCORALIS HYPERINFECTION SYNDROME; STRONGYLOIDIASIS; ANIMAL; CLINICAL TRIAL; COMPLICATION; ISOLATION AND PURIFICATION; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK FACTOR; SHOCK, SEPTIC; SURVIVAL ANALYSIS;

ADULT; ANIMALS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SHOCK, SEPTIC; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; SURVIVAL ANALYSIS;

EID: 84948078030     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-015-0799-1     Document Type: Article

References (40)

1. Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;33:1040–7.
2. Vadlamudi RS, Chi DS, Krishnaswamy G. Intestinal strongyloidiasis and hyperinfection syndrome. Clin Mol Allergy CMA. 2006;4:8.
3. Schär F, Trostdorf U, Giardina F, Khieu V, Muth S, Marti H, et al. Strongyloides stercoralis: global Distribution and Risk Factors. Plos Negl Trop Dis. 2013;7:e2288.
4. Ramanathan R, Nutman T. Strongyloides stercoralis infection in the immunocompromised host. Curr Infect Dis Rep. 2008;10:105–10.
5. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev. 2004;17:208–17.
6. Concha R, Harrington W Jr, Rogers AI. Intestinal strongyloidiasis: recognition, management, and determinants of outcome. J Clin Gastroenterol. 2005;39:203–11.
7. Debussche X, Toublanc M, Camillieri JP, Assan R. Overwhelming strongyloidiasis in a diabetic patient following ACTH treatment and keto-acidosis. Diabète Métabolisme. 1988;14:294–8.
8. Rivera E, Maldonado N, Vélez-García E, Grillo AJ, Malaret G. Hyperinfection syndrome with Strongyloides stercoralis. Ann Intern Med. 1970;72:199–204.
9. Milder JE, Walzer PD, Kilgore G, Rutherford I, Klein M. Clinical features of Strongyloides stercoralis infection in an endemic area of the United States. Gastroenterology. 1981;80:1481–8.
10. Montes M, Sanchez C, Verdonck K, Lake JE, Gonzalez E, Lopez G, et al. Regulatory T cell expansion in HTLV-1 and strongyloidiasis co-infection is associated with reduced IL-5 responses to Strongyloides stercoralis antigen. Plos Negl Trop Dis. 2009;3:e456.
11. Porto AF, Neva FA, Bittencourt H, Lisboa W, Thompson R, Alcântara L, et al. HTLV-1 decreases Th2 type of immune response in patients with strongyloidiasis. Parasite Immunol. 2001;23:503–7.
12. Blankenhaus B, Klemm U, Eschbach M-L, Sparwasser T, Huehn J, Kühl AA, et al. Strongyloidesratti infection induces expansion of Foxp3+ regulatory T cells that interfere with immune response and parasite clearance in BALB/c mice. J Immunol Baltim Md. 1950;2011(186):4295–305.
13. Galioto AM, Hess JA, Nolan TJ, Schad GA, Lee JJ, Abraham D. Role of eosinophils and neutrophils in innate and adaptive protective immunity to larval strongyloides stercoralis in mice. Infect Immun. 2006;74:5730–8.
14. Herbert DR, Lee JJ, Lee NA, Nolan TJ, Schad GA, Abraham D. Role of IL-5 in innate and adaptive immunity to larval Strongyloides stercoralis in mice. J Immunol Baltim Md. 1950;2000(165):4544–51.
15. Kerepesi LA, Hess JA, Nolan TJ, Schad GA, Abraham D. Complement component C3 is required for protective innate and adaptive immunity to larval strongyloides stercoralis in mice. J Immunol Baltim Md. 1950;2006(176):4315–22.
16. Rotman HL, Yutanawiboonchai W, Brigandi RA, Leon O, Gleich GJ, Nolan TJ, et al. Strongyloides stercoralis: eosinophil-dependent immune-mediated killing of third stage larvae in BALB/cByJ mice. Exp Parasitol. 1996;82:267–78.
17. Padigel UM, Hess JA, Lee JJ, Lok JB, Nolan TJ, Schad GA, et al. Eosinophils act as antigen-presenting cells to induce immunity to Strongyloides stercoralis in mice. J Infect Dis. 2007;196:1844–51.
18. Padigel UM, Lee JJ, Nolan TJ, Schad GA, Abraham D. Eosinophils can function as antigen-presenting cells to induce primary and secondary immune responses to Strongyloides stercoralis. Infect Immun. 2006;74:3232–8.
19. Coffman RL, Seymour BW, Hudak S, Jackson J, Rennick D. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science. 1989;245:308–10.
20. Grimaldi JC, Yu NX, Grunig G, Seymour BW, Cottrez F, Robinson DS, et al. Depletion of eosinophils in mice through the use of antibodies specific for C-C chemokine receptor 3 (CCR3). J Leukoc Biol. 1999;65:846–53.
21. Gurish MF, Humbles A, Tao H, Finkelstein S, Boyce JA, Gerard C, et al. CCR3 is required for tissue eosinophilia and larval cytotoxicity after infection with Trichinella spiralis. J Immunol Baltim Md. 1950;2002(168):5730–6.
22. Liu H-C, Hsu J-Y, Chang K-M. Strongyloides stercoralis hyperinfection presenting with symptoms mimicking acute exacerbation of chronic obstructive pulmonary disease. J Chin Med Assoc. 2009;72:442–5.
23. Lagacé-Wiens PRS, Harding GKM. A Canadian immigrant with coinfection of Strongyloides stercoralis and human T-lymphotropic virus 1. Can Med Assoc J. 2007;177:451–3.
24. Igra-Siegman Y, Kapila R, Sen P, Kaminski ZC, Louria DB. Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis. 1981;3:397–407.
25. Adedayo O, Grell G, Bellot P. Hyperinfective strongyloidiasis in the medical ward: review of 27 cases in 5 years. South Med J. 2002;95:711–6.
26. Fardet L, Généreau T, Poirot J-L, Guidet B, Kettaneh A, Cabane J. Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review. J Infect. 2007;54:18–27.
27. Coulter C, Walker DG, Günsberg M, Brown IG, Bligh JF, Prociv P. Successful treatment of disseminated strongyloidiasis. Med J Aust. 1992;157:331–2.
28. Ghoshal UC, Ghoshal U, Jain M, Kumar A, Aggarwal R, Misra A, et al. Strongyloides stercoralis infestation associated with septicemia due to intestinal transmural migration of bacteria. J Gastroenterol Hepatol. 2002;17:1331–3.
29. Kakati B, Dang S, Heif M, Caradine K, McKnight W, Aduli F. Strongyloides duodenitis: case report and review of literature. J Natl Med Assoc. 2011;103:60–3.
30. Gutierrez Y, Bhatia P, Garbadawala ST, Dobson JR, Wallace TM, Carey TE. Strongyloides stercoralis eosinophilic granulomatous enterocolitis. Am J Surg Pathol. 1996;20:603–12.
31. Sipahi AM, Damião AO, Simionato CS, Bonini N, Santos MA, de Moraes-Filho JP, et al. Small bowel bacterial overgrowth in strongyloidiasis. Digestion. 1991;49:120–4.
32. Younis AE, Soblik H, Ajonina-Ekoti I, Erttmann KD, Luersen K, Liebau E, et al. Characterization of a secreted macrophage migration inhibitory factor homologue of the parasitic nematode Strongyloides acting at the parasite-host cell interface. Microbes Infect Inst Pasteur. 2012;14:279–89.
33. Pastrana DV, Raghavan N, FitzGerald P, Eisinger SW, Metz C, Bucala R, et al. Filarial nematode parasites secrete a homologue of the human cytokine macrophage migration inhibitory factor. Infect Immun. 1998;66:5955–63.
34. Suputtamongkol Y, Premasathian N, Bhumimuang K, Waywa D, Nilganuwong S, Karuphong E, et al. Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis. Plos Negl Trop Dis. 2011;5:e1044.
35. Muennig P, Pallin D, Challah C, Khan K. The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States. Epidemiol Infect. 2004;132:1055–63.
36. Hauber HP, Galle J, Chiodini PL, Rupp J, Birke R, Vollmer E, et al. Fatal outcome of a hyperinfection syndrome despite successful eradication of Strongyloides with subcutaneous ivermectin. Infection. 2005;33:383–6.
37. Leung V, Al-Rawahi GN, Grant J, Fleckenstein L, Bowie W. Case report: failure of subcutaneous ivermectin in treating Strongyloides hyperinfection. Am J Trop Med Hyg. 2008;79:853–5.
38. Lichtenberger P, Rosa-Cunha I, Morris M, Nishida S, Akpinar E, Gaitan J, et al. Hyperinfection strongyloidiasis in a liver transplant recipient treated with parenteral ivermectin. Transpl Infect Dis Off J Transplant Soc. 2009;11:137–42.
39. Pacanowski J, Santos MD, Roux A, Maignan CLE, Guillot J, Lavarde V, et al. Subcutaneous ivermectin as a safe salvage therapy in Strongyloides stercoralis hyperinfection syndrome: a case report. Am J Trop Med Hyg. 2005;73:122–4.
40. Santiago M, Leitão B. Prevention of strongyloides hyperinfection syndrome: a rheumatological point of view. Eur J Intern Med. 2009;20:744–8.